Dr. Dennis Salmon, professor and chief of hematology/oncology at UCLA and UCLA IUO physician-scientist, has been awarded the 2019 Lasker-DeBakey Clinical Medical Research Award for the groundbreaking development of breast cancer drug Herceptin (trastuzumab), a lifesaving therapy for women with HER2-positive breast cancer. The award, to be presented on Sept. 20, is widely regarded as America’s top biomedical research prize. UCLA Newsroom >
UCLA researcher uses big data to help optimize cancer treatment. How can datasets help reveal new ways to treat cancer? UCLA Jonsson Cancer Center's Paul Boutros shares how his lab is working in collaboration with research centers around the world to use big data to help develop new ways to fight this disease.
Story on newsroom.ucla.edu >
Dr. Brian Shuch, associate professor of urology and Dr. Sandy Liu, clinical instructor in medicine, hematology-oncology, present an overview of The UCLA Kidney Cancer Program that spans across multiple departments to bring the very best of UCLA to fight a challenging disease.
Amar U. Kishan, MD, UCLA IUO researcher and radiation oncologist, was the lead author on a new UCLA-led study showing that men with low- or intermediate-risk prostate cancer can safely undergo higher doses of radiation over a significantly shorter period of time and still have the same, successful outcomes as from a much longer course of treatment. UCLA Newsroom >
Targeted Treatment of Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to see if the study drug, Trametinib, is safe and effective for the treatment of metastatic castration-resistant prostate cancer. View Clinical Trial >
Artificial Intelligence Performs as Well as Experienced Radiologists in Detecting Prostate Cancer - Left: Ruiming Cao, Dr. Steven Raman & Kyung Sun. Researchers compared the system’s results with readings by UCLA doctors who had more than 10 years of experience. UCLA Newsroom >
